Stanford University
Showing 501-550 of 624 Results
-
Ross Shachter
Associate Professor of Management Science and Engineering
Current Research and Scholarly InterestsProf. Shachter's research has focused on the representation, manipulation, and analysis of uncertainty and probabilistic reasoning in decision systems. As part of this work, he developed the DAVID influence diagram processing system for the Macintosh. He has developed models scheduling patients for cancer follow-up, and analyzing vaccination strategies for HIV and Helobacter pylori.
-
Nigam H. Shah, MBBS, PhD
Professor of Medicine (Biomedical Informatics) and of Biomedical Data Science
Current Research and Scholarly InterestsWe answer clinical questions using aggregate patient data at the bedside. The Informatics Consult Service (https://greenbutton.stanford.edu/) put this idea in action and led to the creation of Atropos Health. We build predictive models that allow taking mitigating actions, keeping the human in the loop.
-
Sumit Shah
Clinical Associate Professor, Medicine - Oncology
Clinical Associate Professor (By courtesy), UrologyBioDr. Sumit Shah is a medical oncologist specializing in the management of advanced urologic malignancies, including prostate, kidney, bladder, and testicular cancers. He serves as an investigator on numerous clinical trials, with a particular focus on novel immunotherapy agents. His academic interests also encompass digital health technologies and innovative healthcare delivery models, both domestically and internationally.
Dr. Shah graduated with distinction in biomedical engineering from Duke University, earned his MD from Stanford University, and completed a Master of Public Health at Harvard University. He trained in internal medicine at the University of California, San Francisco (UCSF), where he remained on faculty for one year before returning to Stanford for his fellowship in medical oncology. He now holds a faculty position in the Department of Medicine (Oncology) at Stanford.
In addition to his clinical and research roles, Dr. Shah serves as Medical Director of Digital Health Integration and Director of Infusion Services at Stanford Hospital. He is also Assistant Dean of Academic Advising in the Stanford School of Medicine. -
Shagufta Shaheen
Clinical Assistant Professor, Medicine - Oncology
BioDr. Shaheen specializes in the gastrointestinal malignancies and she has expertise in treating neuroendocrine tumors (NETs). Following her fellowship in Hematology and Oncology, Dr Shaheen completed an advanced fellowship in Neuroendocrine tumors from Stanford University. The NET advanced fellowship is first of its kind in United State started under the leadership of Dr Pamela Kunz who is the founding Director of the Stanford Neuroendocrine Tumor Program established in 2015. After completing her advanced fellowship, Dr Shaheen joined Stanford Oncology division as Clinical Assistant Professor. Dr Shaheen is involved in further developing the neuroendocrine oncology program at Stanford which serves as a centre of excellence in the treatment of neuroendocrine tumors. Dr Shaheen is actively involved in clinical research and clinical trials. Dr Shaheen is also involved in taking care of patients admitted to the oncology service as well as resident and fellow teaching.
-
Andrew A. Shelton, MD, FACS, FACRS
Clinical Professor, Surgery - General Surgery
Current Research and Scholarly InterestsMultimodality treatment of rectal cancer
Sphincter preserving procedures for rectal cancer
Laparoscopic colon and rectal surgery
Surgical education -
Jeanne Shen
Associate Professor of Pathology
Current Research and Scholarly InterestsGastrointestinal and pancreatobiliary pathology, with major emphasis on GI and pancreatic neoplasia, inflammatory bowel disease, biodesign innovation, and the application of machine learning to digital pathology.
-
Gavin Sherlock
Professor of Genetics
Current Research and Scholarly InterestsEvolution and the adaptive landscape using yeast as a model; Defining yeast transcriptomes; chromosomal evolution in hybrid yeast species
-
Judith Shizuru
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Current Research and Scholarly InterestsTransplantation of defined populations of allogeneic hematopoietic cells. Specifically, the way in which hematopoietic cell grafts alter antigen specific immune responses to allo-, auto- and viral antigens. The cellular and molecular basis of resistance to engraftment of allogeneic hematopoietic stem cells.
-
Linda M. Dairiki Shortliffe
Stanley McCormick Memorial Professor in the School of Medicine, Emerita
Current Research and Scholarly InterestsThe timing for intervention in obstruction in the infant and child is poorly understood.Our group has been interested in trying to define the risks that may be involved in obstructive and infectious uropathies and discovering early signs of damage to the urinary tract and kidney. We have explored ways of imaging the urinary tract using nonionizing radiation (US, MRI). We have studied the relationships of sex steroid hormones, pregnancy, reflux, urinary tract infection and urinary tract function.
-
Joseph Shrager
Professor of Cardiothoracic Surgery
Current Research and Scholarly InterestsIn clinical research, Dr. Shrager studies outcomes in a variety of areas within Thoracic Surgery including: parenchyma-sparing operations and minimally invasive resections for lung cancer, transcervical thymectomy for myasthenia gravis, diaphragm plication, and surgical treatment of emphysema.
Dr. Shrager's lab is focused on the impact of disease states upon the diaphragm. His group published the seminal paper (NEJM) describing diaphragm atrophy assoc'd with mechanical ventilation. -
Surbhi Sidana, MD
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
BioDr. Surbhi Sidana is an Associate Professor of Medicine at Stanford University and specializes in the treatment of multiple myeloma and related disorders. She leads the Myeloma CAR-T/Immunotherapy program at Stanford.
Dr Sidana grew up in Delhi, India. She completed her Internal Medicine Residency at Cleveland Clinic in Cleveland, Ohio, followed by Hematology/Oncology fellowship at Mayo Clinic in Rochester, MN. Following this, she completed an Advanced Hematology Fellowship in Myeloma, Amyloidosis and Related Disorders at Mayo Clinic in Rochester, MN before joining Stanford University as a faculty member in 2019, where she has led the development of the myeloma CAR-T and bispecific antibody program.
Dr Sidana has an active, broad research portfolio that includes clinical trials of novel therapies in myeloma and related disorders, translational research, epidemiologic and patient reported outcome studies. She has a special focus on research with immunotherapies such as CAR-T cell therapy and bispecific antibodies. She has published over 100 research manuscripts. Dr Sidana is the Leader of the Myeloma Disease Focused Group and the Associate Director for Clinical Research in the BMT and Cell Therapy Division at Stanford University. She also co-leads a multi-institutional collaboration on real world outcomes with immunotherapies in myeloma.
Dr Sidana is actively involved in and holds leadership positions in national and international professional societies. She is the Chair of the American Society of Hematology Committee on Communications, and Co-Chairs the Quality-of-Life Committee of the International Myeloma Working Group. She is a member of the SWOG Myeloma Committee and BMT CTN Myeloma Intergroup, where she works with colleagues across the nation to develop innovative and practice changing trials focused on multiple myeloma . -
Arend Sidow
Professor of Pathology and of Genetics
Current Research and Scholarly InterestsWe have a highly collaborative research program in the evolutionary genomics of cancer. We apply well-established principles of phylogenetics to cancer evolution on the basis of whole genome sequencing and functional genomics data of multiple tumor samples from the same patient. Introductions to our work and the concepts we apply are best found in the Newburger et al paper in Genome Research and the Sidow and Spies review in TIGS.
More information can be found here: http://www.sidowlab.org -
Branimir I. Sikic, M. D.
Professor of Medicine (Oncology), Emeritus
Current Research and Scholarly InterestsResearch Interests: cancer pharmacology, mechanisms of resistance to anticancer drugs, regulation and function of MDR1 and tubulin genes, CD47 as a target for activation of anticancer macrophases, Phase I trials of new drugs, gene expression profiling of cancers
-
Robert Sinclair
Charles M. Pigott Professor in the School of Engineering
BioUsing high-resolution transmission electron microscopy, Sinclair studies microelectronic, magnetic thin film microstructure and nanomaterials.
-
Eila C. Skinner
Thomas A. Stamey Research Professor of Urology
Current Research and Scholarly InterestsMy research focuses on outcomes in the treatment of muscle invasive and high-grade non-muscle invasive bladder cancer. This includes identifying markers of prognosis, predictive markers for response to surgery and chemotherapy, and working toward an individualized, multidisciplinary approach to disease management. I have also focused on optimizing the use of lower urinary tract reconstruction in patients undergoing cystectomy, and developing interventions to improve patient quality of life.
-
Stephen Skirboll
Associate Professor of Neurosurgery
Current Research and Scholarly InterestsMy research focuses on screening strategies to identify and characterize cancer stem cells (CSCs) in human gliomas. We are pursuing this in several ways: 1) a novel colony-forming antibody live cell array to identify distinct CSC surface phenotypes, 2) RNAi screens to identify kinases critical for CSC tumorigenicity, 3) high throughput small molecule and chemical screens to identify compounds that selectively kill or target CSCs, and 4) identifying CSCs using the tumor specific EGFRvIII
-
Jan Skotheim
Professor of Biology and, by courtesy, of Chemical and Systems Biology
Current Research and Scholarly InterestsMy overarching goal is to understand how cell growth triggers cell division. Linking growth to division is important because it allows cells to maintain specific size range to best perform their physiological functions. For example, red blood cells must be small enough to flow through small capillaries, whereas macrophages must be large enough to engulf pathogens. In addition to being important for normal cell and tissue physiology, the link between growth and division is misregulated in cancer.
-
Melody Smith, MD, MS
Assistant Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
BioDr. Smith is a board-certified, fellowship-trained medical oncologist and hematologist. She is an Assistant Professor in the Department of Medicine within the Division of Blood & Marrow Transplantation and Cellular Therapy.
She is also a physician-scientist who conducts extensive research. As a medical student, she completed a fellowship at the National Institutes of Health (NIH) in the Clinical Research Training (now, the Medical Research Scholars) Program. Subsequently, after her clinical fellowship, she was a post-doctoral researcher at Memorial Sloan Kettering Cancer Center. Her lab's research focuses on studying the biology of chimeric antigen receptor (CAR) T cells to improve the therapy's efficacy and safety (1) by examining donor (Nature Medicine, 2017) and off-the-shelf CAR T cells in mouse models and (2) by investigating how the intestinal microbiome affects CAR T cell response (Nature Medicine, 2022).
Dr. Smith presents her research findings at regional, national, and international conferences. Additionally, she has co-authored articles on topics in cancer immunology, including cancer immunotherapy, stem cell transplantation, and CAR T cell therapy. Her work has been published in journals such as Nature, Nature Immunology, Nature Medicine, Blood, and Transplantation and Cellular Therapy. She serves as a peer reviewer for publications like NEJM Evidence, Science Advances, Blood, Cancer Cell, and Molecular Therapy. She has also contributed chapters to books, including Pocket Oncology, Current Concepts and Controversies in Hematopoietic Cell Transplantation, and Advanced Concepts in Human Immunology: Prospects for Disease Control.
She has received numerous honors; the American Society of Hematology, the American Society for Clinical Investigation, the Society for Immunotherapy of Cancer, the European Society for Blood and Marrow Transplantation, and several other professional organizations have recognized her achievements as a clinician, researcher, and scholar. -
Stephanie Melissa Smith
Assistant Professor of Pediatrics (Hematology/Oncology)
Current Research and Scholarly InterestsI am involved with clinical research related to cancer survivorship, with a particular focus on late effects of childhood cancer treatments and community partnerships to improve health equity for adolescent/young adult cancer survivors in under-resourced settings.
-
Michael Snyder, Ph.D.
Stanford W. Ascherman Professor of Genetics
Current Research and Scholarly InterestsOur laboratory use different omics approaches to study a) regulatory networks, b) intra- and inter-species variation which differs primarily at the level of regulatory information c) human health and disease. For the later we have established integrated Personal Omics Profiling (iPOP), an analysis that combines longitudinal analyses of genomic, transcriptomic, proteomic, metabolomic, DNA methylation, microbiome and autoantibody profiles to monitor healthy and disease states
-
Samuel So, MD
Lui Hac Minh Professor in the School of Medicine
Current Research and Scholarly InterestsThrough a 4 pronged comprehensive program: translational and clinical research, early detection and treatment, promoting education, awareness and immunization and building partnership, we are working towards the development of new strategies that will lead to the elimination of hepatitis B worldwide and reduce the threat and incidence of liver cancer. Current research efforts focus on evaluating potential new diagnostic and treatment markers and novel targeted therapy for primary liver cancer.
-
Hyongsok Tom Soh
W. M. Keck Foundation Professor of Electrical Engineering, Professor of Radiology (Diagnostic Sciences Laboratory) and of Bioengineering
BioDr. Soh received his B.S. with a double major in Mechanical Engineering and Materials Science with Distinction from Cornell University and his Ph.D. in Electrical Engineering from Stanford University. From 1999 to 2003, Dr. Soh served as the technical manager of MEMS Device Research Group at Bell Laboratories and Agere Systems. He was a faculty member at UCSB before joining Stanford in 2015. His current research interests are in analytical biotechnology, especially in high-throughput screening, directed evolution, and integrated biosensors.
-
Olav Solgaard
Audrey S. Hancock Professor in the School of Engineering
BioThe Solgaard group focus on design and fabrication of nano-photonics and micro-optical systems. We combine photonic crystals, optical meta-materials, silicon photonics, and MEMS, to create efficient and reliable systems for communication, sensing, imaging, and optical manipulation.
-
David Solow-Cordero
Associate Director, High-Throughput Screening, Innovative Medicines Accelerator (IMA)
Current Role at StanfordAssociate Director, High-Throughput Screening Knowledge Center, , Sarafan ChEM-H and Innovative Medicine Accelerator (IMA)
This high-throughput screening (HTS) laboratory allows Stanford researchers and others to discover novel modulators of targets that otherwise would not be practical in industry. The center incorporates instrumentation (purchased with NCRR NIH Instrumentation grant numbers S10RR019513, S10RR026338, S10OD025004, and S10OD026899), databases, compound libraries, and personnel whose previous sole domains were in industry.
Among our instrumentation are a fully automated Molecular Devices ImageXpress Micro Confocal High-Content fluorescence microplate imager, with live cell, fluidics and phase contrast options, an Echo 655 Acoustic Dispense, a Thermo integrated HTS robotic system, a Caliper Life Sciences SciClone ALH3000 and an Agilent Bravo microplate liquid handler, and the BMG Clariostarplus, Tecan Infinite M1000 and M1000 PRO and Molecular Devices FlexStation II 384 fluorescence, luminescence and absorbance multimode microplate readers.
We have over 180,000 small molecules for compound screens, 15,000 cDNAs for genomic screens, and whole genome siRNA libraries targeting the human genome (the siARRAY whole human genome siRNA library from Dharmacon, targeting 21,000 human genes) and the mouse genome (Qiagen mouse whole genome siRNA set V1 against 22,124 genes).
The HTSKC main screening lab is located in ChEM-H W008, the cell-based assay development lab is located in CCSR Room 0133-North Wing, between the Transgenic Mouse Facility, and the Stanford Genomics Facility. -
Scott G. Soltys, MD
Professor of Radiation Oncology (Radiation Therapy) and, by courtesy, of Neurosurgery
Current Research and Scholarly InterestsMy clinical and research interests focus on the development of new radiation techniques involving stereotactic radiosurgery and radiotherapy for the treatment of malignant and benign tumors of the brain and spine, as well as functional disorders such as trigeminal neuralgia.
-
Hong Song, MD, PhD
Assistant Professor of Radiology (Nuclear Medicine)
BioHong Song received his MD from Tulane University School of Medicine and a Ph.D. in Chemical Engineering from Tulane University. He performed research in targeted radionuclide therapy as a postdoctoral fellow at the Johns Hopkins University. Following medical school, he joined Dual pathway Nuclear Medicine and Diagnostic Radiology residency at Stanford. His current research interests include PSMA PET in biochemically recurrent prostate cancer and DOTATATE PET in PRRT for neuroendocrine tumors.
-
Geoffrey Sonn
Associate Professor of Urology and, by courtesy, of Radiology (Body MRI)
Current Research and Scholarly InterestsMy interest is in improving prostate cancer diagnosis through MRI and image-targeted prostate biopsy. In collaboration with radiologists at Stanford, we are working to define the optimal role of MRI in prostate cancer. We hope to improve cancer imaging to the point that some men with elevated PSA may safely avoid prostate biopsy. For those who need biopsy, we are evaluating novel MRI-US fusion targeted biopsy, a technique that greatly improves upon the conventional biopsy method.
-
David Spiegel
Jack, Lulu and Sam Willson Professor of Medicine
On Partial Leave from 10/01/2025 To 05/15/2026Current Research and Scholarly InterestsDr. Spiegel's research program involves mind/body interactions, including cancer progression, the response to traumatic stress, and the effect of hypnosis on the perception of pain and anxiety.
-
Daniel Spielman
Professor of Radiology (Radiological Sciences Lab) and, by courtesy, of Electrical Engineering
Current Research and Scholarly InterestsMy research interests are in the field of medical imaging, particularly magnetic resonance imaging and in vivo spectroscopy. Current projects include MRI and MRS at high magnetic fields and metabolic imaging using hyperpolarized 13C-labeled MRS.
-
James Spudich
Douglass M. and Nola Leishman Professor of Cardiovascular Disease, Emeritus
Current Research and Scholarly InterestsThe general research interest of this laboratory is the molecular basis of cell motility, with a current emphasis on power output by the human heart. We have three specific research interests, the molecular basis of energy transduction that leads to ATP-driven myosin movement on actin, the biochemical basis of the regulation of actin and myosin interaction and their assembly states, and the roles these proteins play in vivo, in cell movement, changes in cell shape and muscle contraction.
-
Sandy Srinivas
Professor of Medicine (Oncology) and, by courtesy, of Urology
Current Research and Scholarly InterestsClinical interests: general oncology, genito-urinary malignancy Research interests: conducting clinical trials in advanced prostate cancer, bladder cancer and renal cell carcinoma
-
Randall Stafford
Professor of Medicine (Stanford Prevention Research Center)
Current Research and Scholarly InterestsAs Director of the SPRC Program on Prevention Outcomes and Practices, my work focuses on cardiovascular disease treatment and prevention, the adoption of new technology and practices, and patterns of physician practice, particularly medication prescribing. Specific interests include measuring and improving the quality of outpatient care, disparities in health care by race, gender, age and socioeconomic status, and interventions to improve prevention outcomes.
-
Marcia L. Stefanick, Ph.D.
Professor (Research) of Medicine (Stanford Prevention Research Center), of Obstetrics and Gynecology and, by courtesy, of Epidemiology and Population Health
Current Research and Scholarly InterestsMarcia L. Stefanick, Ph.D is a Professor of Medicine Professor of Obstetrics and Gynecology, and by courtesy, Professor of Epidemiology and Population Health at Stanford University School of Medicine. Dr. Stefanick’s research focuses on chronic disease prevention (particularly, heart disease, breast cancer, osteoporosis, and dementia) in both women and men. She is currently the Principal Investigator the Women’s Health Initiative (WHI) Extension Study, having been the PI of the Stanford Clinical Center of the landmark WHI Clinical Trials and Observational Study since 1994 and Chair of the WHI Steering and Executive Committees from 1998-2011, as well as PI of the WHI Strong and Healthy (WHISH) Trial which is testing the hypothesis that a DHHS-based physical activity intervention, being delivered to a multi-ethnic cohort of about 24,000 WHI participants across the U.S., aged 68-99 when the trial started in 2015, will reduce major cardiovascular events over 8 years, compared to an equal number of “usual activity” controls. Dr. Stefanick is also PI of the Osteoporotic Study of Men (MrOS) which is continuing to conduct clinical assessments of bone and body composition in survivors of an original cohort of nearly 6000 men aged 65 and over in 2001. As founding Director of the Stanford Women’s Health and Sex Differences in Medicine (WHSDM, “wisdom”) Center, she plays a major role in promoting research and teaching on Sex and Gender in Human Physiology and Disease, Women’s Health and Queer Health and Medicine. Dr. Stefanick also plays major leadership roles at the Stanford School of Medicine, including as co-leader of the Population Sciences Program of the Stanford Cancer Institute, Stanford’s NCI-funded comprehensive cancer center.
Dr. Stefanick obtained her B.A. in biology from the University of Pennsylvania, Philadelphia, PA (1974), then pursued her interest in hormone and sex difference research at the Oregon Regional Primate Research Center, after which she obtained her PhD in Physiology at Stanford University, focusing on reproductive physiology and neuroendocrinology, with exercise physiology as a secondary focus. Her commitment to human research led to a post-doctoral fellowship in Cardiovascular Disease Prevention at the Stanford Prevention Research Center, which has been her academic home for nearly 40 years. -
Aaron F. Straight
Pfeiffer and Herold Families Professor, Professor of Biochemistry and, by courtesy, of Chemical and Systems Biology
Current Research and Scholarly InterestsWe study the biology of chromosomes. Our research is focused on understanding how chromosomal domains are specialized for unique functions in chromosome segregation, cell division and cell differentiation. We are particularly interested in the genetic and epigenetic processes that govern vertebrate centromere function, in the organization of the genome in the eukaryotic nucleus and in the roles of RNAs in the regulation of chromosome structure.
-
John B. Sunwoo, MD
Edward C. and Amy H. Sewall Professor in the School of Medicine and Professor, by courtesy, of Dermatology
Current Research and Scholarly InterestsMy laboratory is focused on two primary areas of research: (1) the immune response to head and neck cancer and to a tumorigenic population of cells within these malignancies called cancer stem cells; (2) the developmental programs of a special lymphocyte population involved in innate immunity called natural killer (NK) cells; and (3) intra-tumor and inter-tumor heterogeneity.
-
James Swartz
James H. Clark Professor in the School of Engineering and Professor of Chemical Engineering and of Bioengineering
Current Research and Scholarly InterestsProgram Overview
The world we enjoy, including the oxygen we breathe, has been beneficially created by biological systems. Consequently, we believe that innovative biotechnologies can also serve to help correct a natural world that non-natural technologies have pushed out of balance. We must work together to provide a sustainable world system capable of equitably improving the lives of over 10 billion people.
Toward that objective, our program focuses on human health as well as planet health. To address particularly difficult challenges, we seek to synergistically combine: 1) the design and evolution of complex protein-based nanoparticles and enzymatic systems with 2) innovative, uniquely capable cell-free production technologies.
To advance human health we focus on: a) achieving the 120 year-old dream of producing “magic bullets”; smart nanoparticles that deliver therapeutics or genetic therapies only to specific cells in our bodies; b) precisely designing and efficiently producing vaccines that mimic viruses to stimulate safe and protective immune responses; and c) providing a rapid point-of-care liquid biopsy that will count and harvest circulating tumor cells.
To address planet health we are pursuing biotechnologies to: a) inexpensively use atmospheric CO2 to produce commodity biochemicals as the basis for a new carbon negative chemical industry, and b) mitigate the intermittency challenges of photovoltaic and wind produced electricity by producing hydrogen either from biomass sugars or directly from sunlight.
More than 25 years ago, Professor Swartz began his pioneering work to develop cell-free biotechnologies. The new ability to precisely focus biological systems toward efficiently addressing new, “non-natural” objectives has proven tremendously useful as we seek to address the crucial and very difficult challenges listed above. Another critical feature of the program is the courage (or naivete) to approach important objectives that require the development and integration of several necessary-but- not-sufficient technology advances. -
Susan M. Swetter, MD
Professor of Dermatology
Current Research and Scholarly Interests1) Early detection of melanoma through enhanced screening, novel imaging technologies, and professional/public education to improve melanoma awareness. 2) Therapeutic prevention of melanoma and other skin cancers in high-risk groups. 4) Epidemiologic and sociodemographic melanoma risk factors. 4) Dermatologist liaison to ECOG-ACRIN Melanoma Committee and Co-founder/Co-Director of the national Melanoma Prevention Working Group, an interdisciplinary collaboration dedicated to melanoma control.
-
Karl G. Sylvester
Professor of Surgery (Pediatric Surgery)
Current Research and Scholarly InterestsScholarly interests include investigation of molecular markers of human disease that provide diagnostic function, serve as targets for possible therapeutic manipulation, or provide insight into mechanisms of human disease. Specific diseases of interest include common conditions of pregnancy, gut microbial ecology and Necrotizing Enterocolitis (NEC).
-
Daniel Sze, MD, PhD
Professor of Radiology (Interventional Radiology)
On Leave from 11/01/2025 To 02/28/2026Current Research and Scholarly InterestsTransarterial administration of chemotherapeutics, radioactive microspheres, and biologics for the treatment of unresectable tumors; management of portal hypertension and complications of cirrhosis (TIPS); treatment of complications of organ transplantation; Venous and pulmonary arterial thrombolysis and reconstruction; Stent and Stent-graft treatment of peripheral vascular diseases, aneurysms, aortic dissections
-
Hua Tang
Professor of Genetics and, by courtesy, of Statistics
Current Research and Scholarly InterestsDevelop statistical and computational methods for population genomics analyses; modeling human evolutionary history; genetic association studies in admixed populations.
-
Jean Y. Tang MD PhD
Professor of Dermatology
Current Research and Scholarly InterestsMy research focuses on 2 main areas:
1. Skin cancer:
- New therapeutics to treat and prevent non-melanoma skin cancer, especially by targeting the Hedgehog signaling pathway for BCC tumors
- Genomic analysis of drug-resistant cancers
- Identifying risk factors for skin cancer in the Women's Health Initiative
2. Epidermolysis Bullosa: gene therapy and protein therapy to replace defective/absent Collagen 7 in children and adults with Recessive Dystrophic EB -
Sindy Tang
Associate Professor of Mechanical Engineering, Senior Fellow at the Woods Institute for the Environment and Professor, by courtesy, of Radiology and of Bioengineering
Current Research and Scholarly InterestsThe long-term goal of Dr. Tang's research program is to harness mass transport in microfluidic systems to accelerate precision medicine and material design for a future with better health and environmental sustainability.
Current research areas include: (I) Physics of droplets in microfluidic systems, (II) Interfacial mass transport and self-assembly, and (III) Applications in food allergy, single-cell wound repair, and the bottom-up construction of synthetic cell and tissues in close collaboration with clinicians and biochemists at the Stanford School of Medicine, UCSF, and University of Michigan.
For details see https://web.stanford.edu/group/tanglab/ -
Sami Gamal-Eldin Tantawi
Professor of Particle Physics and Astrophysics, Emeritus
BioFor over a decade I have advocated for dedicated research efforts on the basic physics of room temperature high gradient structures and new initiatives for the associated RF systems. This required demanding multidisciplinary collaboration to harness limited resources. The basic elements of the research needed to be inclusive to address not only the fundamentals of accelerator structures but also the fundamentals of associated technologies such as RF manipulation and novel microwave power sources. These basic research efforts were not bundled with specific developments for an application or a general program. The emerging technologies promise a broad, transformational impact.
With this underlying philosophy in mind, in 2006 the US High Gradient Research Collaboration for which I am the spokesman was formed. SLAC is the host of this collaboration, which comprises MIT, ANL, University of Maryland and University of Colorado, NRL and a host of SBIR companies. This led to the revitalization of this research area worldwide. The international collaborative effort grew to include KEK in Japan, INFN, Frascati in Italy, the Cockcroft Institute in the UK, and the CLIC team at CERN.
This effort led to a new understanding of the geometrical effects affecting high gradient operations. The collaborative work led to new advances in understanding the gradient limits of photonic band gap structures. Now we have a new optimization methodology for accelerator structure geometries and ongoing research on alternate and novel materials. These efforts doubled the usable gradient in normal conducting high gradient linacs to more than 100 MV/m, thus revitalizing the spread of the technology to other applications including compact Inverse Compton Scattering gamma-ray sources for national security applications, and compact proton linacs for cancer therapy.
